Ambryon Biosciences

AAV9.45 Serotype

Liver-detargeted AAV9 variant engineered to reduce hepatic uptake while maintaining cardiac and skeletal muscle transduction.

TropismCardiac muscle, skeletal muscle (reduced liver)

Characteristics

5-fold reduction in liver uptake versus AAV9. Maintained cardiac and skeletal muscle transduction efficiency. Rational mutagenesis approach. Improved therapeutic index for muscle-targeted applications.

Applications

Cardiac gene therapy with reduced liver exposure. Muscular dystrophies. Systemic muscle-directed gene delivery.

Sequence1 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Pulicherla et al. (2011). Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther — Pulicherla 2011 AAV9 Variants

Identifiers & revision